General

Title
Advanced chronic kidney disease (CKD): percent of patients treated with an erythropoietin or analogue.

Source(s)

Measure Domain

Primary Measure Domain
Clinical Quality Measures: Process

Secondary Measure Domain
Does not apply to this measure

Brief Abstract

Description
This measure assesses the percent of patients treated with an erythropoietin or analogue among patients with advanced chronic kidney disease (CKD) who were anemic, had an anemia work-up and are on iron therapy for three months or are iron replete.

Rationale
Anemia is common in patients with advanced chronic kidney disease (CKD) and can lead to a variety of detrimental effects. In addition to the direct effects of anemia on performance and ischemic symptoms, it has also been suggested that mortality and major complications during end-stage renal disease (ESRD) are associated with anemia that develops early in the course of CKD. Correcting anemia before the initiation of renal replacement therapy (RRT) may improve health outcomes.

Many patients in this population have erythropoietin-responsive anemia and treatment of such anemia with erythropoietin is associated with improved intermediate measures.

Evidence for Rationale


Primary Health Components

Advanced chronic kidney disease; anemia; iron replete; erythropoietin

Denominator Description

The number of adult patients with advanced chronic kidney disease (CKD) for at least three months, not currently receiving renal replacement therapy who were anemic, had an anemia work-up, and are on iron therapy for three months or are iron replete
Numerator Description
The number of patients from the denominator treated with an erythropoietin or analogue

Evidence Supporting the Measure

Type of Evidence Supporting the Criterion of Quality for the Measure
A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
A formal consensus procedure, involving experts in relevant clinical, methodological, public health and organizational sciences
A systematic review of the clinical research literature (e.g., Cochrane Review)

Additional Information Supporting Need for the Measure
- Two studies have identified anemia as being prevalent in patients with advanced chronic kidney disease and it is also clear that the severity of anemia increases considerably with worsening renal function.
- Anemia is associated with increased mortality, detrimental effects on cardiac function, exercise capacity, quality of life, and cognitive function.

Evidence for Additional Information Supporting Need for the Measure


Extent of Measure Testing
Unspecified

State of Use of the Measure

State of Use
Current routine use

Current Use
not defined yet

Application of the Measure in its Current Use

Measurement Setting
Ambulatory/Office-based Care
Hospital Outpatient

Professionals Involved in Delivery of Health Services
not defined yet

Least Aggregated Level of Services Delivery Addressed
Individual Clinicians or Public Health Professionals

Statement of Acceptable Minimum Sample Size
Unspecified

Target Population Age
Age greater than or equal to 18 years

Target Population Gender
Either male or female
National Strategy for Quality Improvement in Health Care

National Quality Strategy Aim
Better Care

National Quality Strategy Priority
Prevention and Treatment of Leading Causes of Mortality

Institute of Medicine (IOM) National Health Care Quality Report Categories

IOM Care Need
Living with Illness

IOM Domain
Effectiveness

Data Collection for the Measure

Case Finding Period
Unspecified

Denominator Sampling Frame
Patients associated with provider

Denominator (Index) Event or Characteristic
Clinical Condition
Diagnostic Evaluation
Patient/Individual (Consumer) Characteristic
Therapeutic Intervention

Denominator Time Window
not defined yet

Denominator Inclusions/Exclusions
Inclusions

Adult patients age 18 years and older with chronic kidney disease stage 4 or 5 (glomerular filtration rate [GFR] less than or equal to 30 mL/min/1.73 m²) for at least three months not currently receiving renal replacement therapy who were anemic*, had an anemia work-up** and are on iron therapy for 3 months (90 days) or are iron replete

*Hemoglobin [Hb] level less than 12 g/dL for women and less than 13 g/dL for men

**Operationally defined as at least one test in each of the following categories:

- Tests to detect anemia
  - Hemoglobin (Hgb)
  - Hematocrit (Hct)
- Tests to detect iron deficiency
  - Serum iron
  - Total Iron Binding Capacity (TIBC),
  - Percent transferrin saturation (TSAT [serum iron X 100 divided by TIBC])
- Test for occult blood in stool

Exclusions

Unspecified

Exclusions/Exceptions

not defined yet

Numerator Inclusions/Exclusions

Inclusions

The number of patients from the denominator who are treated with an erythropoietin or analogue

Exclusions

Unspecified

Numerator Search Strategy

Episode of care

Data Source

Administrative clinical data
Laboratory data
Paper medical record
Pharmacy data

Type of Health State

Does not apply to this measure

Instruments Used and/or Associated with the Measure

Unspecified

Computation of the Measure
Measure Specifies Disaggregation
Does not apply to this measure

Scoring
Rate/Proportion

Interpretation of Score
Desired value is a higher score

Allowance for Patient or Population Factors
not defined yet

Standard of Comparison
not defined yet

Identifying Information

Original Title
Number of patients treated with an erythropoietin or analogue / number of patients who were anemic, had an anemia work-up and are on iron therapy for 3 months or are iron replete.

Measure Collection Name
Clinical Performance Measures on Appropriate Patient Preparation for Renal Replacement Therapy

Measure Set Name
Anemia Recommendations

Submitter
Renal Physicians Association - Medical Specialty Society

Developer
Renal Physicians Association - Medical Specialty Society

Funding Source(s)
Ortho Biotech Products, LP
Composition of the Group that Developed the Measure

W. Kline Bolton, MD, Working Group Chair, University of Virginia School of Medicine, Charlottesville, VA; William F. Owen, Jr., MD, President, RPA, Duke University School of Medicine Durham, NC; Baxter Healthcare Corp., McGaw Park, IL; Dale Singer, MHA, Executive Director, RPA.

Content Experts: Jack Coburn, MD, UCLA School of Medicine, West Los Angeles V.A. Healthcare Center, West Los Angeles, CA; William Haley, MD, Mayo Clinic, Jacksonville, FL; Annamaria Kausz, MD, New England Medical Center, Boston, MA; Adeera Levin, MD, St. Paul's Hospital, Vancouver, BC; William Mitch, MD, University of Texas Medical Branch, Galveston, TX; Patricia Painter, PhD, University of California, San Francisco, CA; Michael Rocco, MD, MSCE, Wake Forest University School of Medicine, Winston-Salem, NC.

Association Representatives: Carolyn Atkins, RN, BS, CCTC, National Kidney Foundation, Medical City Dallas Hospital, Dallas, TX; Shelley Clark, RN, National Renal Administrators Association, FMC North Roanoke Dialysis, Roanoke, VA; Paul Eggers, PhD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD; Lori Fedje, RD, LD, NKF Council on Renal Nutrition, Pacific Northwest Renal Services, Portland, OR; Richard Goldman, MD, Renal Physicians Association, Renal Medicine Associates, Emeritus Albuquerque, NM; Joel Greer, PhD, Centers for Medicare and Medicaid Services, Baltimore, MD; Richard Lafayette, MD, American Society of Nephrology, Stanford University School of Medicine, Stanford, CA; Eugene Z. Oddone, MD, American College of Physicians - American Society of Internal Medicine, Durham VA Medical Center, Durham, NC; Victoria Norwood, MD, American Society of Pediatric Nephrology, University of Virginia, Charlottesville, VA; Paul M. Palevsky, MD, Forum of ESRD Networks, University of Pittsburgh School of Medicine, VA Pittsburgh Health Care System, Pittsburgh, PA; Sandy Peckens, MSW, NKF Council of Nephrology Social Workers, Merrimack Valley Nephrology, Methuen, MA; Venkateswara Rao, MD, American Society of Transplantation, Hennepin County Medical Center, Minneapolis, MN; Charlotte Thomas Hawkins, PhD, RN, CNN, American Nephrology Nurses Association, Rutgers, The State University of New Jersey, Burlington, NJ; Joseph White, American Association of Kidney Patients.

Methodologists: David B. Matchar, MD, FACP, Director, Duke Center for Clinical Health Policy Research and Co-Director, Duke Evidence-based Practice Center, Durham, NC; Douglas C. McCrory, MD, MHS, Co-Director Duke Evidence-based Practice Center, Durham, NC; Joseph A. Coladorato, MD, Duke Institute of Renal Outcomes Research & Health Policy, Durham, NC; Preston S. Klassen, MD, MHS, Duke Institute of Renal Outcomes Research & Health Policy, Durham, NC; Meenal B. Patwardhan, MD, MHSA, Duke Center for Clinical Health Policy Research and Duke Evidence-based Practice Center, Durham, NC; Doral N. Reddan, MD, MHS, Duke Institute of Renal Outcomes Research & Health Policy, Durham, NC; Olivier T. Rutschmann, MD, MPH, Duke Center for Clinical Health Policy Research, Durham, NC; William S. Yancy, Jr., MD, MHS, Duke University Medical Center, Durham, NC.

Medical Editor: Rebecca N. Gray, DPhil, Duke Evidence-based Practice Center, Durham, NC.

Project Manager and Editor: Emily G. Shurr, MA, Duke Evidence-based Practice Center, Durham, NC.

Financial Disclosures/Other Potential Conflicts of Interest

There were none disclosed.

Adaptation

This measure was not adapted from another source.

Date of Most Current Version in NQMC

2002 Oct

Measure Maintenance

Unspecified

Date of Next Anticipated Revision
Measure Status

This is the current release of the measure.
The measure developer reaffirmed the currency of this measure in March 2016.

Measure Availability

Source not available electronically.

For more information, contact the Renal Physicians Association (RPA) at 1700 Rockville Pike, Suite 220, Rockville, MD 20852; Phone: 301-468-3515; Fax: 301-468-3511; Web site: www.renalmd.org; E-mail: rpa@renalmd.org.

NQMC Status

This NQMC summary was completed by ECRI on May 2, 2003. The information was verified by the Renal Physicians Association on May 27, 2003.
This NQMC summary was retrofitted into the new template on May 5, 2011.
The information was reaffirmed by the measure developer on March 11, 2016.

Copyright Statement

This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.

For more information, contact RPA at 1700 Rockville Pike, Suite 220, Rockville, MD 20852; phone: 301-468-3515; fax: 301-468-3511; Web site: www.renalmd.org; e-mail: rpa@renalmd.org.

Production

Source(s)


Disclaimer

NQMC Disclaimer

The National Quality Measures Clearinghouse® (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.
NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.